Clinical Trials Sponsored by Merck Serono (GFI)
Total 202 results
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedLupus Erythematosus, SystemicUnited States, Bulgaria
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyNot yet recruitingOvarian CancerUnited States, Germany
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyRecruitingDermatomyositis | PolymyositisUnited States, Italy, Spain, Greece, Czechia, United Kingdom, Poland
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedLymphoma | Refractory or Relapsed Solid TumorsKorea, Republic of, United States, Canada, Belgium, Denmark
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyActive, not recruitingA Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)Multiple SclerosisUnited States
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyActive, not recruitingSolid TumorsKorea, Republic of, United States, Spain, United Kingdom, Russian Federation, Argentina, Australia, Italy, Japan, Belgium, Brazil, Czechia, France, Germany, Hungary, Romania, Turkey, Bulgaria, Mexico, Poland, Thailand, Ukraine
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyActive, not recruitingSystemic Lupus ErythematosusKorea, Republic of, United States, Taiwan, China, Poland, Brazil, Argentina, Chile, Philippines, Australia, Colombia, Bulgaria, Mexico, Serbia, Greece, Spain, Israel, Japan, Mauritius, Moldova, Republic of, Romania, South Africa
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid TumorsKorea, Republic of, United States, Belgium, Spain, Italy, Taiwan, Canada, Australia, United Kingdom, Germany, France, Japan
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedRelapsing-remitting Multiple SclerosisSpain, Czechia, Bulgaria, Serbia, Russian Federation, Ukraine, Poland, Slovakia
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedFirst Line Non-Small Cell Lung CancerSpain, United States, Hungary, Israel, China, Korea, Republic of, Taiwan, Czechia, Russian Federation, Australia, Brazil, Lebanon, Serbia, Thailand, Canada, Slovakia, Ukraine, Bulgaria, Italy, Netherlands, New Zealand, Poland, Belgium, Turk... and more
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedCervical CancerUnited States, Spain, Japan
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyActive, not recruitingNon-small Cell Lung CancerUnited States, Korea, Republic of, Taiwan, Spain, Hong Kong, Argentina, China, Netherlands, France, Brazil, Belgium, Canada, Germany, Greece, Italy, Japan, Turkey, Ukraine
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompleted
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminated
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedCholangiocarcinoma | Biliary Tract Cancer | Gallbladder CancerKorea, Republic of, United States, Taiwan, China, Argentina, Australia, Brazil, Chile, France, Germany, Italy, Japan, Poland, Spain, United Kingdom
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedUterine Cervical NeoplasmsKorea, Republic of, United States, France, Belgium, China, Argentina, Spain, Australia, Russian Federation, Brazil, Hungary, Japan
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedCarcinoma, Non-Small-Cell LungUnited States, Belgium, France
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSmall-cell Lung CancerSpain, Belgium, United States, China, Japan, Italy, France
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedLocally Advanced Rectal CancerUnited States, Spain
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompleted
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedMetastatic Renal Cell Carcinoma | Advanced Solid TumorsUnited States
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid TumorsUnited States, Korea, Republic of, Taiwan, France, United Kingdom, Belgium, Czechia, Germany, Poland
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedRelapsing-remitting Multiple SclerosisUnited States, Germany
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyWithdrawnBreast Cancer | Advanced Solid Tumor
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedAdvanced Solid TumorsSpain, United States, Netherlands, Hungary, Italy, France, Belgium
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedSmall Cell Lung CancerBelgium, Denmark, Italy, United States, Bulgaria, Canada, Czechia, Germany, Hungary, Poland, Romania, Spain, United Kingdom
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedCarcinoma, Non-Small-Cell LungSpain, United States, Taiwan, Belgium, Denmark, Switzerland, Argentina, Israel, Italy, Croatia, United Kingdom, Korea, Republic of, Russian Federation, Slovakia, Japan, Bulgaria, Poland, Hungary, Australia, Turkey, Peru, Chile, Mexico, Czech... and more
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedAdvanced Solid TumorUnited States
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedSystemic Sclerosis-associated Interstitial Lung DiseaseUnited States, Canada, Italy, Poland, Spain, Argentina, Australia, Israel, United Kingdom
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedRheumatoid ArthritisUnited States, Germany
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyNot yet recruitingAdvanced Solid TumorUnited States, Germany
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyRecruitingNon-Small Cell Lung CancerKorea, Republic of, United States, Japan, Spain, Italy, Belgium, France, Germany
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyRecruitingColorectal CancerUnited States, Spain, Japan
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyRecruitingMetastatic or Locally Advanced Unresectable Solid TumorsUnited States, Canada, Spain
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyRecruitingCancerUnited States, Israel, Spain, Finland, France, Belgium, Netherlands, United Kingdom, Canada, Italy, Germany, Sweden, Austria, Czechia, Portugal
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyActive, not recruitingMultiple SclerosisUnited States
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedCholangiocarcinoma | Biliary Tract Cancer | Gallbladder CancerKorea, Republic of, United States, Taiwan, Italy, France, China, Japan, Spain, United Kingdom
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedAdvanced Solid TumorsCanada, United States
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyActive, not recruitingAdvanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Lung Adenocarcinoma Stage IIIB/IVSpain, Taiwan, United States, Korea, Republic of, Netherlands, Israel, Belgium, Italy, China, France, Germany, Japan, Poland, Austria, Switzerland
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedMultiple MyelomaUnited States, France
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedUnresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal JunctionUnited States, Spain, Italy, Australia, Russian Federation, Taiwan, Korea, Republic of, Thailand, Canada, Turkey, Germany, Romania, United Kingdom, Hungary, Brazil, France, Japan
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedCoronavirus Disease 2019United States, Brazil, Philippines
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedRelapsing-remitting Multiple SclerosisUnited States, Germany
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedUnresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric Cancer Third LineSpain, Italy, Australia, Korea, Republic of, Belgium, France, Poland, United States, Czechia, Germany
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedMetastatic or Locally Advanced Unresectable Solid TumorsUnited States
-
Merck KGaA, Darmstadt, GermanySmerud Medical Research International AS; Merck Serono NorwayCompletedRelapsing Remitting Multiple Sclerosis (RRMS)Norway
-
Merck KGaA, Darmstadt, GermanySmerud Medical Research International AS; Merck Serono NorwayCompleted
-
ART Fertility Clinics LLCMerck Serono International SACompletedProgesterone ResistanceUnited Arab Emirates
-
Merck KGaA, Darmstadt, GermanyEMD Serono Canada Inc.CompletedClinically Isolated SyndromeCanada